Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data at 2024 San Antonio Breast Cancer Symposium (SABCS)
ICYMI: Plus Therapeutics presented our ReSPECT-LM Phase 1 interim data for Breast Cancer patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium (SABCS). The presentation highlighted the potential of Rhenium (186Re) Obisbemeda as a treatment for Leptomeningeal Metastases (LM), showcasing its ability to target and treat cerebrospinal fluid circulating tumor cells (CSF-CTCs).
This positive interim data brings hope to the breast cancer community, especially for patients battling metastatic breast cancer (MBC) and Leptomeningeal Metastases, a challenging and often overlooked complication of cancer.
Key Highlights from the ReSPECT-LM Presentation:
- Single Intrathecal Dose of Rhenium (186Re) Obisbemeda: The treatment showed favorable responses in multiple clinical evaluation metrics, including a reduction in cerebrospinal fluid circulating tumor cell count, improved imaging results, and positive clinical outcomes.
- Clinical Trial Expansion: Plans for both single-dose and multiple-dose expansion trials are underway, with trials set to begin in 2025 to further explore the potential of Rhenium Obisbemeda as a treatment for Leptomeningeal Metastases in breast cancer patients.
For more details on the presentation, view the full link to presentation here:
2024 SABCS Presentation
For additional insights, read our full Press Release here:
Press Release
Why This Data Matters to Breast Cancer Patients
Leptomeningeal Metastases (LM) are a significant complication for many breast cancer patients, particularly those with metastatic breast cancer (MBC). LM occurs when cancer cells spread to the meninges, the protective layers surrounding the brain and spinal cord. This often leads to neurological symptoms and poor outcomes, making effective treatment crucial.
The ReSPECT-LM trial, utilizing Rhenium (186Re) Obisbemeda, represents a potential breakthrough in treating LM in breast cancer patients, offering hope for improved survival rates and quality of life.
What’s Next for ReSPECT-LM?
As we look ahead to 2025, Plus Therapeutics plans to advance both single-dose and multiple-dose expansion trials to further evaluate the safety and efficacy of Rhenium Obisbemeda for Leptomeningeal Metastases treatment. These trials will play a critical role in shaping the future of metastatic breast cancer (MBC) therapy and potentially improving treatment outcomes for patients with LM.
Stay Updated on Future Developments
If you’re interested in clinical trials for Leptomeningeal Metastases and metastatic breast cancer, be sure to follow our updates and stay informed on the latest advancements.
🔔 For More Information on ReSPECT-LM and Breast Cancer Treatment:
- Presentation Link: View Full Presentation at SABCS 2024
- Press Release: Read Full Press Release
Recent Comments